References
- Vlahakes G. J.R., Lee E. E., Jacobs La Raia P. J., Austen W. G. Hemodynamic effects and oxygen transport properties of a new blood substitute in a model of massive blood replacement. J. Thorac. Cardtovasc. Surg. 1990; 100: 379–388
- Feola M., Simoni J., Tran R., Canizaro P. O. Nephrotoxicity of hemoglobin solutions. Biomat., Art. Cells, Art. Org. 1990; 18(2)233–249
- Savitsky J. P., Doczi J., Black J., Arnold J. D. A clinical safety trial of stroma-free hemoglobin. Clin. Pharmacol. Ther. 1978; 23(1)73–80
- Feola M., Simoni J.R., Tran Lox C. D., Canizaro P. C. The toxicity of erythrocytic stroma. The Red Cell: Seventh Ann Arbor Conference. Published by Alan R. Liss, Inc., 1989; 361–382
- Feola M.J., Simoni P. C., Canizaro Tran R., Raschbaum F., Behal F. J. Toxicity of polymerized hemoglobin solutions. Surg. Gyn. Obstet. 1988; 166: 211–222
- White C. T.A.J., Murray J. R., Greene D. J., Smith F., Medina G. T., Makovec Martin E. J., Bolin R. B. Toxicity of human hemoglobin solution infused into rabbits. J. Lab. Clin. Med. 1986; 108(2)121–131
- Feola M., Simoni I., Dobke M., Canizaro P. C. Complement activation and the toxicity of “stroma-free” hemoglobin solutions. Circ. Shock 1986; 18(4)340, abst. 31
- Flynn J., Jereski L., Baker S. The FDA is stanching the flow of blood substitutes. Business Week. May 21, 1990; 42–43
- Fratantoni J. C. Points to consider in the safety evaluation of hemoglobin-based oxygen carriers. Transfusion 1991; 31(4)369–371
- Zager R. A., Gamelin L. M. Pathogenetic mechanisms in experimental hemoglobinuric acute renal failure. Am. J. Physiol. 1989; 256: F446–F455
- Malik A. B., Selig W. M., Burhop K. E. Cellular and humoral mediators of pulmonary edema. Lung 1985; 163: 193–219